Navigation Links
3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
Date:2/11/2010

SHENYANG, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a Phase I clinical trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA). NuPIAO is a highly glycosylated ESA (erythropoiesis-stimulating agent) with extended half-life and increased biologic activity. Pre-clinical results showed a promising pharmacokinetic profile which would allow a once weekly injection schedule of NuPIAO in humans. NuPIAO will be investigated to treat anemia associated with both chronic kidney disease and cancer.

"This submission represents another important milestone in our effort to extend our market leading EPO franchise and continue to serve the needs of patients in China," said Dr. Jing Lou, CEO of 3SBio. "It is a direct result of our dedicated R&D effort to generate an innovative pipeline and create long term value for shareholders."

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

Safe Harbor Statement'/>"/>

SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... of HIV infection and the number of deaths due to ... rate across the globe. It has been estimated that the ... in 2013, with the rates for children being even much ... infection rates has been the improved access to antiretroviral drugs ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Hospitals in Western Pennsylvania Earn Designation, PITTSBURGH, ... named Allegheny General Hospital, UPMC Presbyterian Shadyside and ... Rare Cancers., Complex and rare cancers comprise ... making it difficult for patients to locate or,research ...
... has announced,development of a chemically synthesized vaccine specific ... patented Replikins(TM) technology.,When the vaccine was administered orally ... Taura virus. The specificity of the protective,effect was ... active,regions in the vaccine, and as a result ...
... Prescribing of Copaxone over an Interferon-Beta Therapy, According to a ... ... Resources, WALTHAM, Mass., March 11 Decision Resources, one ... issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient share among ...
Cached Biology Technology:Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... CAMBRIDGE, MA -- MIT chemical engineers have devised a ... that are released slowly over a few weeks. When ... induces the body to rapidly form new bone that ... This type of coated scaffold could offer a dramatic ... which involves transplanting bone from another part of the ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... may help to identify which depressed patients will ... signal, detectable by noninvasive imaging, also holds clues ... for drug development, say National Institutes of Health ... of several such markers, including factors detectable in ...
... pollution and heavy fishingare adding insult to injury in ... by the Wildlife Conservation Society and the University of ... found that pollution and overfishing on reef systems have ... wormsthat further degrade corals, a discovery that underlines the ...
... University of Oklahoma research team has been awarded a five-year, ... that can lead to a greater understanding of human diseases ... infections. The goal of the NIH grant is to ... research in Oklahoma. "This is the first NIH ...
Cached Biology News:Brain signal IDs responders to fast-acting antidepressant 2Brain signal IDs responders to fast-acting antidepressant 3Brain signal IDs responders to fast-acting antidepressant 4Brain signal IDs responders to fast-acting antidepressant 5Brain signal IDs responders to fast-acting antidepressant 6Microbes, sponges, and worms add to coral reef woes 2Microbes, sponges, and worms add to coral reef woes 3OU research group awarded $9.7 million NIH CoBRE grant in structural biology 2
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... Polystyrene covers can be ... Ridged covers for stacking ... Non-ridged covers for use with ... covers, ridged and non-ridged, are ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
... made from an inert polymer with a unique ... 384 split septum caps for use with 384-well ... PCR when used in conjunction with screw or ... standard pipetting equipment 384 septum caps may ...
Biology Products: